Display options
Share it on

Evid Based Complement Alternat Med. 2012;2012:617085. doi: 10.1155/2012/617085. Epub 2012 Oct 14.

Elimination of cancer stem-like "side population" cells in hepatoma cell lines by chinese herbal mixture "tien-hsien liquid".

Evidence-based complementary and alternative medicine : eCAM

Chih-Jung Yao, Chi-Tai Yeh, Liang-Ming Lee, Shuang-En Chuang, Chuan-Feng Yeh, Wan-Ju Chao, Tung-Yuan Lai, Gi-Ming Lai

Affiliations

  1. Cancer Center, Wan Fang Hospital, Taipei Medical University, Taipei 11696, Taiwan ; Center of Excellence for Cancer Research, Taipei Medical University, Taipei, Taiwan ; Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan.

PMID: 23097677 PMCID: PMC3477562 DOI: 10.1155/2012/617085

Abstract

There are increasing pieces of evidence suggesting that the recurrence of cancer may result from a small subpopulation of cancer stem cells, which are resistant to the conventional chemotherapy and radiotherapy. We investigated the effects of Chinese herbal mixture Tien-Hsien Liquid (THL) on the cancer stem-like side population (SP) cells isolated from human hepatoma cells. After sorting and subsequent culture, the SP cells from Huh7 hepatoma cells appear to have higher clonogenicity and mRNA expressions of stemness genes such as SMO, ABCG2, CD133, β-catenin, and Oct-4 than those of non-SP cells. At dose of 2 mg/mL, THL reduced the proportion of SP cells in HepG2, Hep3B, and Huh7 cells from 1.33% to 0.49%, 1.55% to 0.43%, and 1.69% to 0.27%, respectively. The viability and colony formation of Huh7 SP cells were effectively suppressed by THL dose-dependently, accompanied with the inhibition of stemness genes, e.g., ABCG2, CD133, and SMO. The tumorigenicity of THL-treated Huh7 SP cells in NOD/SCID mice was also diminished. Moreover, combination with THL could synergize the effect of doxorubicin against Huh7 SP cells. Our data indicate that THL may act as a cancer stem cell targeting therapeutics and be regarded as complementary and integrative medicine in the treatment of hepatoma.

References

  1. Carcinogenesis. 2008 Dec;29(12):2289-97 - PubMed
  2. Cancer Res. 2007 Mar 1;67(5):2187-96 - PubMed
  3. Cancer Cell. 2012 Mar 20;21(3):430-46 - PubMed
  4. Breast Cancer Res Treat. 2010 Aug;122(3):777-85 - PubMed
  5. Clin Cancer Res. 2002 Jan;8(1):22-8 - PubMed
  6. BMC Cancer. 2010 Apr 30;10:175 - PubMed
  7. Curr Pharm Des. 2007;13(33):3400-16 - PubMed
  8. Hepatology. 2006 Jul;44(1):23-6 - PubMed
  9. Cancer Lett. 2010 Feb 1;288(1):1-9 - PubMed
  10. Cancer Metastasis Rev. 2010 Sep;29(3):383-94 - PubMed
  11. Evid Based Complement Alternat Med. 2011;2011:984154 - PubMed
  12. Int J Biol Sci. 2011 Apr 26;7(5):517-35 - PubMed
  13. Cancer Res. 2007 May 15;67(10):4827-33 - PubMed
  14. Acta Biochim Biophys Sin (Shanghai). 2008 Sep;40(9):819-29 - PubMed
  15. Pediatr Res. 2007 Sep;62(3):239 - PubMed
  16. Gastroenterology. 2007 Jun;132(7):2542-56 - PubMed
  17. J Biol Chem. 2007 Mar 2;282(9):6854-62 - PubMed
  18. Am J Chin Med. 2005;33(4):559-71 - PubMed
  19. Planta Med. 2008 Nov;74(14):1693-700 - PubMed
  20. Biochem Biophys Res Commun. 2006 Dec 29;351(4):820-4 - PubMed
  21. Trends Mol Med. 2008 Oct;14(10):450-60 - PubMed
  22. Clin Cancer Res. 2010 Jun 15;16(12):3130-40 - PubMed
  23. Adv Enzyme Regul. 1984;22:27-55 - PubMed
  24. Hepatology. 2006 Jul;44(1):240-51 - PubMed
  25. Cancer Res. 2010 Jun 15;70(12):5004-13 - PubMed
  26. Development. 2006 Jan;133(1):3-14 - PubMed
  27. Cancer Lett. 2008 Sep 8;268(1):1-9 - PubMed
  28. Oncogene. 2008 Mar 13;27(12):1749-58 - PubMed
  29. Int J Cancer. 2007 Apr 1;120(7):1444-50 - PubMed
  30. Expert Opin Ther Targets. 2007 Jul;11(7):915-27 - PubMed
  31. Cancer Res. 2007 Sep 1;67(17):8216-22 - PubMed

Publication Types